Optimizing therapy sequencing for HR+ HER2- metastatic breast cancer

Sequencing taxanes before CDK4/6 inhibitors may improve survival outcomes in mBC patients

INDICATION
Breast
BIOMARKER
HER2

Kaplan-Meier survival curves comparing CDK4/6 first and Taxane first treatments for breast cancer.
rwOS anchored on 1L start date in (blue) patients receiving 1L CDK4/6i treatment and 2L taxane treatment compared to (black) patients receiving 1L taxane treatment and 2L CDK4/6i treatment.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Three abstract data distributions displayed as shapes made of small, colored squares.

Sacituzumab govitecan and tumor microenvironment shifts in metastatic triple-negative breast cancer

2026-07-01
CXCL/SPP1 (CS)
Breast
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract data visualization showing a grid of blue, black, and brown dots in patterns.

TP53 mutations are enriched in HER2-positive biliary tract cancer and drive poor outcomes

2026-07-01
Biliary Tract Cancer
TP53
HER2
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Unable to determine image content.

ESR1 mutations and copy number loss in breast cancer

2026-05-26
Breast
ESR1